Outcomes of Mechanical Thrombectomy for Patients With Stroke Presenting With Low Alberta Stroke Program Early Computed Tomography Score in the Early and Extended Window.
Aged
Aged, 80 and over
Asia
Brain Ischemia
/ diagnosis
Carotid Artery, Internal
/ surgery
Cohort Studies
Europe
Female
Humans
Male
Middle Aged
Retrospective Studies
Risk Assessment
/ methods
Stroke
/ diagnosis
Thrombectomy
/ methods
Tomography, X-Ray Computed
/ methods
Treatment Outcome
United States
Journal
JAMA network open
ISSN: 2574-3805
Titre abrégé: JAMA Netw Open
Pays: United States
ID NLM: 101729235
Informations de publication
Date de publication:
01 12 2021
01 12 2021
Historique:
entrez:
8
12
2021
pubmed:
9
12
2021
medline:
18
1
2022
Statut:
epublish
Résumé
Limited data are available about the outcomes of mechanical thrombectomy (MT) for real-world patients with stroke presenting with a large core infarct. To investigate the safety and effectiveness of MT for patients with large vessel occlusion and an Alberta Stroke Program Early Computed Tomography Score (ASPECTS) of 2 to 5. This retrospective cohort study used data from the Stroke Thrombectomy and Aneurysm Registry (STAR), which combines the prospectively maintained databases of 28 thrombectomy-capable stroke centers in the US, Europe, and Asia. The study included 2345 patients presenting with an occlusion in the internal carotid artery or M1 segment of the middle cerebral artery from January 1, 2016, to December 31, 2020. Patients were followed up for 90 days after intervention. The ASPECTS is a 10-point scoring system based on the extent of early ischemic changes on the baseline noncontrasted computed tomography scan, with a score of 10 indicating normal and a score of 0 indicating ischemic changes in all of the regions included in the score. All patients underwent MT in one of the included centers. A multivariable regression model was used to assess factors associated with a favorable 90-day outcome (modified Rankin Scale score of 0-2), including interaction terms between an ASPECTS of 2 to 5 and receiving MT in the extended window (6-24 hours from symptom onset). A total of 2345 patients who underwent MT were included (1175 women [50.1%]; median age, 72 years [IQR, 60-80 years]; 2132 patients [90.9%] had an ASPECTS of ≥6, and 213 patients [9.1%] had an ASPECTS of 2-5). At 90 days, 47 of the 213 patients (22.1%) with an ASPECTS of 2 to 5 had a modified Rankin Scale score of 0 to 2 (25.6% [45 of 176] of patients who underwent successful recanalization [modified Thrombolysis in Cerebral Ischemia score ≥2B] vs 5.4% [2 of 37] of patients who underwent unsuccessful recanalization; P = .007). Having a low ASPECTS (odds ratio, 0.60; 95% CI, 0.38-0.85; P = .002) and presenting in the extended window (odds ratio, 0.69; 95% CI, 0.55-0.88; P = .001) were associated with worse 90-day outcome after controlling for potential confounders, without significant interaction between these 2 factors (P = .64). In this cohort study, more than 1 in 5 patients presenting with an ASPECTS of 2 to 5 achieved 90-day functional independence after MT. A favorable outcome was nearly 5 times more likely for patients with low ASPECTS who had successful recanalization. The association of a low ASPECTS with 90-day outcomes did not differ for patients presenting in the early vs extended MT window.
Identifiants
pubmed: 34878550
pii: 2786939
doi: 10.1001/jamanetworkopen.2021.37708
pmc: PMC8655598
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e2137708Subventions
Organisme : NCATS NIH HHS
ID : UL1 TR001863
Pays : United States
Investigateurs
Dileep R Yavagal
(DR)
Eric C Peterson
(EC)
J Mocco
(J)
Johanna T Fifi
(JT)
Christopher P Kellner
(CP)
Mohammad El-Ghanem
(M)
Kyle M Fargen
(KM)
Patrick A Brown
(PA)
Stavropoula I Tjoumakaris
(SI)
M Reid Gooch
(MR)
Nabeel A Herial
(NA)
Brian L Hoh
(BL)
Nohra Chalouhi
(N)
Nitin Goyal
(N)
Daniel A Hoit
(DA)
Fernanda Rodriguez-Erazú
(F)
Jan Liman
(J)
Kaustubh S Limaye
(KS)
Edgar A Samaniego
(EA)
Charles M Cawley
(CM)
Gustavo Pradilla
(G)
Brian M Howard
(BM)
Waldo R Guerrero
(WR)
João C Reis
(JC)
Russell Cerejo
(R)
Alex Brehm
(A)
Références
PLoS One. 2015 Nov 04;10(11):e0141571
pubmed: 26536226
J Neurointerv Surg. 2017 Sep;9(9):823-829
pubmed: 27550306
N Engl J Med. 2015 Mar 12;372(11):1019-30
pubmed: 25671798
J Neurointerv Surg. 2019 Jun;11(6):545-553
pubmed: 30389899
J Neurol Neurosurg Psychiatry. 2005 Nov;76(11):1528-33
pubmed: 16227545
J Neurointerv Surg. 2018 Dec;10(12):1209-1217
pubmed: 29666180
J Stroke Cerebrovasc Dis. 2017 May;26(5):e78-e79
pubmed: 28318954
Lancet Neurol. 2018 Oct;17(10):895-904
pubmed: 30264728
J Neurointerv Surg. 2020 Apr;12(4):350-355
pubmed: 31401563
Stroke. 2013 Jan;44(1):73-9
pubmed: 23233383
Hypertension. 2019 May;73(5):951-960
pubmed: 30852920
N Engl J Med. 2015 Jun 11;372(24):2296-306
pubmed: 25882510
Stroke. 2019 Apr;50(4):880-888
pubmed: 30827193
Lancet. 2016 Apr 23;387(10029):1723-31
pubmed: 26898852
Lancet Neurol. 2016 Jun;15(7):685-694
pubmed: 27302238
Front Neurol. 2019 Jan 09;9:1119
pubmed: 30687210
Hypertension. 2020 Mar;75(3):730-739
pubmed: 31928111
N Engl J Med. 2018 Feb 22;378(8):708-718
pubmed: 29364767
Lancet Neurol. 2019 Jan;18(1):46-55
pubmed: 30413385
JAMA Netw Open. 2020 Apr 1;3(4):e203767
pubmed: 32347948
J Neurointerv Surg. 2015 Aug;7(8):551-8
pubmed: 24916415
Heart Lung. 2008 May-Jun;37(3):190-5
pubmed: 18482630
J Neurointerv Surg. 2018 Jan;10(1):5-9
pubmed: 29079663
N Engl J Med. 2018 Jan 4;378(1):11-21
pubmed: 29129157
Stroke. 2015 Oct;46(10):3020-35
pubmed: 26123479
Stroke. 2018 Nov;49(11):2801-2807
pubmed: 30355218
Stroke. 2019 Dec;50(12):e344-e418
pubmed: 31662037
J Neurointerv Surg. 2020 Aug;12(8):747-752
pubmed: 31772043
Ann Neurol. 2020 Mar;87(3):419-433
pubmed: 31916270